Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination in Phase 1 Study, Reported by Johnson & Johnson

March 14, 2017 Johnson & Johnson announced that final Phase 1 clinical trial data published in JAMA: The Journal of the American Medical Association show that the investigational “prime-boost” Ebola vaccine regimen of Janssen Pharmaceutical Companies induced a durable immune response in 100 percent of healthy volunteers one year following vaccination. The Oxford Vaccine Group at the University … Continue reading Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination in Phase 1 Study, Reported by Johnson & Johnson

Advertisements

Results from Phase 3 Study Show Significant Efficacy of Guselkumab in Treatment of Moderate to Severe Plaque Psoriasis

March 3, 2017 Janssen Research & Development, LLC has announced new findings from two pivotal Phase 3 studies reporting the safety and efficacy of guselkumab in the treatment of adults with moderate to severe plaque psoriasis. Data from the VOYAGE 2 study showed that patients treated with guselkumab experienced substantial improvements in skin clearance and … Continue reading Results from Phase 3 Study Show Significant Efficacy of Guselkumab in Treatment of Moderate to Severe Plaque Psoriasis

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – November 2016

New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used … Continue reading Top Pharma News – November 2016

Janssen Submits Application Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab to EMA for Treating Moderate-to-Severe Plaque Psoriasis

November 25 2016 Janssen-Cilag International NV has announced about the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) that seeks approval of guselkumab for treating adults with moderate to severe plaque psoriasis. Guselkumab is a human monoclonal antibody targeting the protein interleukin (IL)-23, which plays an important role in developing immune-mediated … Continue reading Janssen Submits Application Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab to EMA for Treating Moderate-to-Severe Plaque Psoriasis

Biosimilars

Biosimilar Products and Its Commercial Potential

The increasing demand for medicines and other biologic products paved the way to the development of methods that can speed up its production in order to meet the needs of its consumers. One of which is the utilization of biosimilar product, which is defined by the U.S. Food and Drug Administration (FDA) as ‘a biological … Continue reading Biosimilar Products and Its Commercial Potential

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Fall 2016

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen … Continue reading Pharma Oncology | Top News – Fall 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – September and October, 2016

  Bristol-Myers Squibb’s ORENCIA® (abatacept) is Approved by European Commission for the Treatment of Adult Patients with Rheumatoid Arthritis September 6, 2016 Bristol-Myers Squibb Company has announced that the European Commission has approved ORENCIA ® (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, combined with methotrexate (MTX), for treating highly active and progressive disease in adult patients with rheumatoid … Continue reading Top Pharma News – September and October, 2016

U.S. FDA Approves Vermox™ Chewable (Mebendazole) for Treating both Children and Adults with Whipworm and Roundworm Infections

Oct 19, 2016 Janssen Pharmaceuticals, Inc. has announced that the Food and Drug Administration (FDA) of U.S. has approved VERMOXTM  CHEWABLE (mebendazole chewable 500mg tablets) for treating patients, both adults and children, with gastrointestinal infections caused by Trichuris trichiura (whipworm) and Ascaris lumbricoides (roundworm). Around the world, this new tablet formulation can provide alternative treatment for millions of children … Continue reading U.S. FDA Approves Vermox™ Chewable (Mebendazole) for Treating both Children and Adults with Whipworm and Roundworm Infections

Treatment outcome data from The Prostate Cancer Registry presented for the first time at the ESMO Congress 2016

Oct 10, 2016 Janssen-Cilag International NV has presented the first reported primary treatment outcome data from The Prostate Cancer Registry at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark. The Prostate Cancer Registry is the first and largest prospective study of men with metastatic castration-resistant prostate cancer (mCRPC) in Europe. The preliminary data … Continue reading Treatment outcome data from The Prostate Cancer Registry presented for the first time at the ESMO Congress 2016